Thomas A Waldmann

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Journal for immunotherapy of cancer

Leukemia & lymphoma

Journal of immunology (Baltimore, Md. : 1950)

National Cancer Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Cancer Institute Jul 01 1956

United States

Branch chief :: lymphoid malignancy Branch NCI NIH

Publications

Noriko Sato, Richard N Bamford, Bonita R Bryant, Yutaka Tagaya, Thomas A Waldmann
Accessory cells precondition naïve T cells and regulatory T cells for cytokine-mediated proliferation. Proceedings of the National Academy of Sciences of the United States of America 120 (15) (2023)
Kevin C Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William Douglas Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati V Gupta, Rom S Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer 9 (11) (2022)
John A Hangasky, Wei Chen, Sigrid P Dubois, Anusara Daenthanasanmak, Jürgen R Müller, Ralph Reid, Thomas A Waldmann, Daniel V Santi
A very long-acting IL-15: implications for the immunotherapy of cancer. Journal for immunotherapy of cancer 10 (1) (2022)
Sigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R Bryant, Michael N Petrus, Liyanage P Perera, Jürgen R Müller, Joanna H Shih, Thomas A Waldmann, Kevin C Conlon
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. Journal for immunotherapy of cancer 9 (4) (2021)
Sigrid Dubois, Thomas A Waldmann, Jürgen R Müller
Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice. Journal of immunology (Baltimore, Md. : 1950) 207 (4) (2021)
Yunlong He, Nagesh Pasupala, Huijun Zhi, Batsuhk Dorjbal, Imran Hussain, Hsiu-Ming Shih, Sharmistha Bhattacharyya, Roopa Biswas, Milos D Miljkovic, Oliver John Semmes, Thomas A Waldmann, Andrew L Snow, Chou-Zen Giam
NF-κB-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. Proceedings of the National Academy of Sciences of the United States of America 118 (10) (2021)
Zhihui Song, Wei Wei, Wenming Xiao, Essel D Al-Saleem, Reza Nejati, Liqi Chen, Jiejing Yin, Joseph Fabrizio, Michael N Petrus, Thomas A Waldmann, Yibin Yang
Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America 117 (46) (2020)
Chalet Tan, Thomas A Waldmann
Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges. Expert opinion on drug delivery 17 (7) (2020)
Joseph Roswarski, Mark Roschewski, Christopher Melani, Stefania Pittaluga, Andrea Lucas, Seth M Steinberg, Elaine S Jaffe, Thomas A Waldmann, Wyndham H Wilson
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leukemia & lymphoma 60 (8) (2019)

Thomas A Waldmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas A Waldmann